A detailed history of Metis Global Partners, LLC transactions in Biogen Inc. stock. As of the latest transaction made, Metis Global Partners, LLC holds 8,374 shares of BIIB stock, worth $1.25 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
8,374
Previous 8,003 4.64%
Holding current value
$1.25 Million
Previous $1.86 Million 12.51%
% of portfolio
0.05%
Previous 0.06%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

BUY
$189.07 - $236.8 $70,144 - $87,852
371 Added 4.64%
8,374 $1.62 Million
Q2 2024

Aug 06, 2024

BUY
$190.52 - $236.72 $21,528 - $26,749
113 Added 1.43%
8,003 $1.86 Million
Q1 2024

May 06, 2024

BUY
$212.02 - $267.71 $4,028 - $5,086
19 Added 0.24%
7,890 $1.7 Million
Q4 2023

Feb 06, 2024

SELL
$222.59 - $267.94 $12,465 - $15,004
-56 Reduced 0.71%
7,871 $2.04 Million
Q3 2023

Nov 07, 2023

BUY
$253.3 - $285.89 $253,046 - $285,604
999 Added 14.42%
7,927 $2.04 Million
Q2 2023

Aug 07, 2023

SELL
$275.25 - $318.06 $23,946 - $27,671
-87 Reduced 1.24%
6,928 $1.97 Million
Q1 2023

May 08, 2023

BUY
$256.56 - $292.34 $18,728 - $21,340
73 Added 1.05%
7,015 $1.95 Million
Q4 2022

Feb 07, 2023

BUY
$252.44 - $306.72 $408,952 - $496,886
1,620 Added 30.44%
6,942 $1.92 Million
Q3 2022

Nov 08, 2022

BUY
$194.69 - $268.46 $26,867 - $37,047
138 Added 2.66%
5,322 $1.42 Million
Q2 2022

Aug 08, 2022

BUY
$187.54 - $223.02 $416,901 - $495,773
2,223 Added 75.08%
5,184 $1.06 Million
Q1 2022

May 03, 2022

BUY
$193.77 - $244.14 $198,420 - $249,999
1,024 Added 52.87%
2,961 $623,000
Q4 2021

Feb 11, 2022

BUY
$223.92 - $287.77 $433,733 - $557,410
1,937 New
1,937 $465,000

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $21.5B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Metis Global Partners, LLC Portfolio

Follow Metis Global Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Metis Global Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Metis Global Partners, LLC with notifications on news.